Back to top

oncology-screening: Archive

Zacks Equity Research

MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success

Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.

MRKNegative Net Change BAYRYNegative Net Change MRUSNegative Net Change VRNANegative Net Change

Ahan Chakraborty

Will RXRX's Shift in Pipeline Focus Help Restore Investor Faith?

Recursion Pharmaceuticals axes three drug programs after weak study data, but shifts focus to more promising candidates like REC-4881 to regain ground.

SDGRNegative Net Change RLAYNegative Net Change RXRXNegative Net Change